Emerging immunotargets and immunotherapies in prostate cancer

Montironi, Rodolfo; Santoni, Matteo; Sotte, Valeria; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Matrana, Marc R; Moch, Holger; Berardi, Rossana; Scarpelli, Marina

doi:10.2174/1389450117666160217123304

Citations

Citation copied

Montironi, R., Santoni, M., Sotte, V., Cheng, L., Lopez-Beltran, A., Massari, F., Matrana, M. R., Moch, H., Berardi, R., & Scarpelli, M. (2016). Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets, 17(7), 777–782. https://doi.org/10.2174/1389450117666160217123304

Abstract

Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic